Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06203002 · ClinicalTrials.gov registry record · Phase 2
A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
A Phase 2 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 496
- Enrollment target
NCT06203002 is a Phase 2 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 496 participants.
The verdict
NCT06203002, a Phase 2 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 496 participants
- Enrollment target
Study Summary
Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP. Please see study website: https://diabeticpainstudy.com/
Interventions
- DRUG Placebo (blinded)
- DRUG LX9211 (blinded)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2023-11-29 |
| Est. Completion | 2025-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06203002
The ClinicalTrials.gov registry entry for NCT06203002 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 496 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo (blinded) is the first listed.
NCT06203002 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06203002 about?
NCT06203002 is a clinical study titled "A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)". Evaluation of the efficacy of LX9211 compared to placebo in reducing DPNP. Please see study website: https://diabeticpainstudy.com/
What is the current status of trial NCT06203002?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 496 participants. The study started on 2023-11-29. Estimated completion is 2025-02-24.
What interventions are being tested in trial NCT06203002?
The interventions under investigation include: Placebo (blinded) (DRUG), LX9211 (blinded) (DRUG).
Who is sponsoring clinical trial NCT06203002?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.